149 related articles for article (PubMed ID: 25218305)
1. Targeting the transforming growth factor (TGF)-β cascade in the remodeling heart: benefits and perils.
Frangogiannis NG
J Mol Cell Cardiol; 2014 Nov; 76():169-71. PubMed ID: 25218305
[No Abstract] [Full Text] [Related]
2. Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5.
Engebretsen KV; Skårdal K; Bjørnstad S; Marstein HS; Skrbic B; Sjaastad I; Christensen G; Bjørnstad JL; Tønnessen T
J Mol Cell Cardiol; 2014 Nov; 76():148-57. PubMed ID: 25169971
[TBL] [Abstract][Full Text] [Related]
3. An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.
Rausch MP; Hahn T; Ramanathapuram L; Bradley-Dunlop D; Mahadevan D; Mercado-Pimentel ME; Runyan RB; Besselsen DG; Zhang X; Cheung HK; Lee WC; Ling LE; Akporiaye ET
Anticancer Res; 2009 Jun; 29(6):2099-109. PubMed ID: 19528470
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction.
Tan SM; Zhang Y; Connelly KA; Gilbert RE; Kelly DJ
Am J Physiol Heart Circ Physiol; 2010 May; 298(5):H1415-25. PubMed ID: 20154262
[TBL] [Abstract][Full Text] [Related]
5. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.
Fu K; Corbley MJ; Sun L; Friedman JE; Shan F; Papadatos JL; Costa D; Lutterodt F; Sweigard H; Bowes S; Choi M; Boriack-Sjodin PA; Arduini RM; Sun D; Newman MN; Zhang X; Mead JN; Chuaqui CE; Cheung HK; Zhang X; Cornebise M; Carter MB; Josiah S; Singh J; Lee WC; Gill A; Ling LE
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):665-71. PubMed ID: 18202322
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor.
Sakata Y; Chancey AL; Divakaran VG; Sekiguchi K; Sivasubramanian N; Mann DL
Basic Res Cardiol; 2008 Jan; 103(1):60-8. PubMed ID: 18034274
[TBL] [Abstract][Full Text] [Related]
7. Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload.
Koitabashi N; Danner T; Zaiman AL; Pinto YM; Rowell J; Mankowski J; Zhang D; Nakamura T; Takimoto E; Kass DA
J Clin Invest; 2011 Jun; 121(6):2301-12. PubMed ID: 21537080
[TBL] [Abstract][Full Text] [Related]
8. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
Long L; Crosby A; Yang X; Southwood M; Upton PD; Kim DK; Morrell NW
Circulation; 2009 Feb; 119(4):566-76. PubMed ID: 19153267
[TBL] [Abstract][Full Text] [Related]
9. Soluble transforming growth factor-beta1 receptor II might inhibit transforming growth factor-beta-induced myofibroblast differentiation and improve ischemic cardiac function after myocardial infarction in rats.
Lian R; Chen Y; Xu Z; Zhang X
Coron Artery Dis; 2010 Sep; 21(6):369-77. PubMed ID: 20613497
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of transforming growth factor beta signaling decreases infection and prevents heart damage in acute Chagas' disease.
Waghabi MC; de Souza EM; de Oliveira GM; Keramidas M; Feige JJ; Araújo-Jorge TC; Bailly S
Antimicrob Agents Chemother; 2009 Nov; 53(11):4694-701. PubMed ID: 19738024
[TBL] [Abstract][Full Text] [Related]
11. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
Wan X; Li ZG; Yingling JM; Yang J; Starbuck MW; Ravoori MK; Kundra V; Vazquez E; Navone NM
Bone; 2012 Mar; 50(3):695-703. PubMed ID: 22173053
[TBL] [Abstract][Full Text] [Related]
12. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
13. Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.
Li HY; Wang Y; Heap CR; King CH; Mundla SR; Voss M; Clawson DK; Yan L; Campbell RM; Anderson BD; Wagner JR; Britt K; Lu KX; McMillen WT; Yingling JM
J Med Chem; 2006 Mar; 49(6):2138-42. PubMed ID: 16539403
[TBL] [Abstract][Full Text] [Related]
14. Left ventricular hypertrophy: virtuous intentions, malign consequences.
Pokharel S; Sharma UC; Pinto YM
Int J Biochem Cell Biol; 2003 Jun; 35(6):802-6. PubMed ID: 12676167
[TBL] [Abstract][Full Text] [Related]
15. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
[TBL] [Abstract][Full Text] [Related]
16. Design, 3D QSAR modeling and docking of TGF-β type I inhibitors to target cancer.
Ajay Kumar TV; Athavan AAS; Loganathan C; Saravanan K; Kabilan S; Parthasarathy V
Comput Biol Chem; 2018 Oct; 76():232-244. PubMed ID: 30077902
[TBL] [Abstract][Full Text] [Related]
17. Elevated insulin-like growth factor-I and transforming growth factor-beta 1 and their receptors in patients with idiopathic hypertrophic obstructive cardiomyopathy. A possible mechanism.
Li G; Li RK; Mickle DA; Weisel RD; Merante F; Ball WT; Christakis GT; Cusimano RJ; Williams WG
Circulation; 1998 Nov; 98(19 Suppl):II144-9; discussion II149-50. PubMed ID: 9852896
[TBL] [Abstract][Full Text] [Related]
18. Salt, salt sensitivity, and the endothelium: a pathway to discovery of molecular mechanisms.
Agarwal R
Hypertension; 2013 Nov; 62(5):831-3. PubMed ID: 24041945
[No Abstract] [Full Text] [Related]
19. Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure.
Okada H; Takemura G; Kosai K; Li Y; Takahashi T; Esaki M; Yuge K; Miyata S; Maruyama R; Mikami A; Minatoguchi S; Fujiwara T; Fujiwara H
Circulation; 2005 May; 111(19):2430-7. PubMed ID: 15867170
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction.
Ikeuchi M; Tsutsui H; Shiomi T; Matsusaka H; Matsushima S; Wen J; Kubota T; Takeshita A
Cardiovasc Res; 2004 Dec; 64(3):526-35. PubMed ID: 15537506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
